ALGS Q2 2022 Earnings — Aligos Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ALGSAligos Therapeutics, Inc.

$45M

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M+139.0% YoY

Gross Profit

$4M100.0% margin

Operating Income

-$20M-552.2% margin

Net Income

-$20M-539.5% margin

EPS (Diluted)

$-0.47

QoQ Revenue Growth

+43.6%

Cash Flow

Operating Cash Flow

-$25M

Free Cash Flow

-$25M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$183M

Total Liabilities

$46M

Stockholders' Equity

$137M

Cash & Equivalents

$71M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$2M	+139.0%
Gross Profit	$4M	$2M	+139.0%
Operating Income	-$20M	-$30M	+31.0%
Net Income	-$20M	-$30M	+33.2%